Insulin icodec/semaglutide, or IcoSema, is a combination medication of insulin icodec and semaglutide in development for type 2 diabetes by Novo Nordisk. It is injected once weekly.[1][2][3]
| Combination of | |
|---|---|
| Insulin icodec | Insulin analog |
| Semaglutide | GLP-1 receptor agonist |
| Clinical data | |
| Trade names | IcoSema |
| Legal status | |
| Legal status |
|
References
edit- ^ Kalra, Sanjay; Bhattacharya, Saptarshi; Kapoor, Nitin (August 2021). "Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)". Diabetes Therapy. 12 (8): 2133–2147. doi:10.1007/s13300-021-01113-y. ISSN 1869-6953. PMC 8342688. PMID 34268675.
- ^ "CTG Labs - NCBI". clinicaltrials.gov. Retrieved 5 November 2023.
- ^ "Novo Nordisk's Insulin Products, Pipeline May Energize The Stock (NYSE:NVO) | Seeking Alpha". seekingalpha.com. 12 February 2020. Retrieved 5 November 2023.